ASCENDIS PHARMA A/S - AMERICAN DEPOSITARY SHARES

195,30

26-августа-25 10:39:14

15 мин. задержка

Акции

+4,93

+2,59%

Сегодняшний диапазон

189,00 - 195,50

ISIN

N/A

Источник

NASDAQ

NetDania - New 12 months High: ASCENDIS PHARMA A/S - AMERICAN DEPOSITARY SHARES

17 мар 2025 06:45:02 Источник NetDania Notify
NetDania - New 12 months High: ASCENDIS PHARMA A/S - AMERICAN DEPOSITARY SHARES

03 мар 2025 06:45:07 Источник NetDania Notify
NetDania - New 12 months High: ASCENDIS PHARMA A/S - AMERICAN DEPOSITARY SHARES

28 фев 2025 09:27:23 Источник NetDania Notify
Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference

24 фев 2025 13:01:00 Источник Nasdaq GlobeNewswire
Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs

12 фев 2025 13:05:00 Источник Nasdaq GlobeNewswire
Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results

12 фев 2025 13:01:00 Источник Nasdaq GlobeNewswire
Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025

05 фев 2025 13:01:00 Источник Nasdaq GlobeNewswire
Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference

12 янв 2025 14:00:00 Источник Nasdaq GlobeNewswire
Ascendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

06 янв 2025 05:30:00 Источник Nasdaq GlobeNewswire
YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults

19 дек 2024 05:30:00 Источник Nasdaq GlobeNewswire
New InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26

16 дек 2024 05:30:00 Источник Nasdaq GlobeNewswire
FDA Accepts Ascendis Pharma’s Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

12 дек 2024 13:01:00 Источник Nasdaq GlobeNewswire
Ascendis Pharma Reports Third Quarter 2024 Financial Results

14 ноя 2024 13:01:00 Источник Nasdaq GlobeNewswire
Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024

07 ноя 2024 13:01:00 Источник Nasdaq GlobeNewswire
Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases

04 ноя 2024 04:00:00 Источник Nasdaq GlobeNewswire
New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024

30 сен 2024 05:30:00 Источник Nasdaq GlobeNewswire
Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

30 сен 2024 05:30:00 Источник Nasdaq GlobeNewswire
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

19 сен 2024 17:16:32 Источник Nasdaq GlobeNewswire
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

18 сен 2024 13:04:11 Источник Nasdaq GlobeNewswire
Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo

16 сен 2024 04:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.